Tiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Up 128.0% in January

Tiziana Life Sciences Ltd (NASDAQ:TLSA) was the target of a significant growth in short interest in January. As of January 31st, there was short interest totalling 1,220,000 shares, a growth of 128.0% from the January 15th total of 535,000 shares. Based on an average daily volume of 595,600 shares, the days-to-cover ratio is presently 2.0 days. Currently, 1.7% of the company’s stock are sold short.

Tiziana Life Sciences Price Performance

Shares of NASDAQ TLSA traded up $0.05 during mid-day trading on Friday, reaching $0.79. The company had a trading volume of 348,594 shares, compared to its average volume of 1,207,392. The stock has a fifty day moving average of $0.77 and a two-hundred day moving average of $0.92. Tiziana Life Sciences has a 12-month low of $0.41 and a 12-month high of $1.74.

Institutional Trading of Tiziana Life Sciences

A number of hedge funds have recently made changes to their positions in TLSA. Zhang Financial LLC lifted its position in shares of Tiziana Life Sciences by 24.2% in the third quarter. Zhang Financial LLC now owns 69,387 shares of the company’s stock worth $67,000 after purchasing an additional 13,500 shares in the last quarter. Sanctuary Advisors LLC purchased a new stake in shares of Tiziana Life Sciences in the third quarter worth approximately $864,000. Geode Capital Management LLC lifted its position in shares of Tiziana Life Sciences by 12.4% in the fourth quarter. Geode Capital Management LLC now owns 245,722 shares of the company’s stock worth $171,000 after purchasing an additional 27,041 shares in the last quarter. Finally, Bison Wealth LLC purchased a new stake in shares of Tiziana Life Sciences in the fourth quarter worth approximately $30,000.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.